Search results for "From ACP Journal Club"
In drug-refractory IBS, group CBT with interoceptive exposure improved symptoms and quality of life at 13 wk
Given the results of this small, randomized trial, a head-to-head comparison of multidisciplinary care versus group cognitive behavioral therapy (CBT) delivered over the internet for patients with irritable bowel syndrome (IBS) is now warranted, an ACP Journal Club commentary noted.
https://gastroenterology.acponline.org/archives/2022/08/26/10.htm
26 Aug 2022
In active Crohn disease, risankizumab increased clinical remission and endoscopic response at 12 wk
While the FDA has now approved risankizumab for adults with moderate to severe Crohn disease, understanding of the drug's role in relation to other biologic therapies is limited by broad exclusion criteria in randomized controlled trials, an ACP Journal Club commentary noted.
https://gastroenterology.acponline.org/archives/2022/10/28/10.htm
28 Oct 2022
In active UC, upadacitinib induced and maintained remission
JAK inhibitors, such as upadacitinib, represent an advance in the management of patients with ulcerative colitis (UC); however, it remains unclear whether the balance of efficacy versus risk favors one drug over the others, according to an ACP Journal Club commentary.
https://gastroenterology.acponline.org/archives/2022/10/28/11.htm
28 Oct 2022
In adults using oral anticoagulants, PPI use may be associated with lower risk for upper GI bleeding
An ACP Journal Club commentary on the meta-analysis stressed the importance of assessing patients' underlying risk for GI bleeding and using overall clinical risk to guide shared decision making in those at higher risk or with lower baseline bleeding tolerance.
https://gastroenterology.acponline.org/archives/2022/11/18/9.htm
18 Nov 2022
Recommendations for pharmacologic management of IBS with diarrhea, constipation
New guidelines suggest that there are several effective drugs available for irritable bowel syndrome (IBS), but a more detailed analysis indicates that the best treatments increase the rate of response by only 15% versus placebo, an ACP Journal Club commentary said.
https://gastroenterology.acponline.org/archives/2022/11/18/8.htm
18 Nov 2022
In adults receiving mechanical ventilation, selective decontamination of the digestive tract reduces hospital mortality
While findings of the meta-analysis did not show evidence of increased incidence of antimicrobial-resistant organisms, the review included data from regions that have very low levels of antimicrobial resistance, an ACP Journal Club commentary noted.
https://gastroenterology.acponline.org/archives/2023/03/24/11.htm
24 Mar 2023
In older patients receiving aspirin, H pylori eradication reduced hospitalization or death due to peptic ulcer bleeding at 2.5 y
Several limitations of the trial may affect the extent to which the results will change current practice of Helicobacter pylori eradication in patients receiving aspirin, especially older patients, an ACP Journal Club commentary noted.
https://gastroenterology.acponline.org/archives/2023/04/21/6.htm
21 Apr 2023
In H pylori infection, vonoprazan plus high-dose amoxicillin was noninferior to B-quadruple therapy for eradication
While the dual therapy provides another promising option for Helicobacter pylori eradication, replicating the findings in more diverse patient populations would provide additional reassurance about widespread use, an ACP Journal Club commentary noted.
https://gastroenterology.acponline.org/archives/2023/05/26/8.htm
26 May 2023
In persons with constipation or IBS-C, kiwifruit vs. psyllium increased spontaneous bowel movements
Findings of the randomized trial bolster recommendations of diet manipulation and lifestyle modifications for chronic constipation syndromes, an ACP Journal Club commentary said.
https://gastroenterology.acponline.org/archives/2023/05/26/7.htm
26 May 2023
In moderately to severely active UC, etrasimod increased remission at 12 and 52 wk but increased adverse events
Given their overall safety and convenience, etrasimod and other oral sphingosine-1-phosphate receptor modulators can be considered as first-line therapy in clinically appropriate patients with ulcerative colitis (UC) who do not respond to 5-aminosalicylic acid medications, an ACP Journal Club commentary said.
https://gastroenterology.acponline.org/archives/2023/07/28/7.htm
28 Jul 2023